Importance of ABCC1 for cancer therapy and prognosis

References

• Abbott BL. (2003). ABCG2 (BCRP) Expression in normal and malignant hematopoietic cells. Hematol Oncol 21:115–130
   PubMed Web of Science ®Google Scholar
• Akan I, Akan S, Akca H, et al. (2005). Multidrug resistance-associated protein 1 (MRP1) mediated vincristine resistance: Effects of N-acetylcysteine and Buthionine sulfoximine. Cancer Cell Int 5:22
   PubMed Web of Science ®Google Scholar
• Alexander D, Yamamoto T, Kato S, Kasai S. (1999). Histopathological assessment of multidrug resistance in gastric cancer: Expression of P-glycoprotein, multidrug resistance-associated protein, and lung-resistance protein. Surg Today 29:401–406
   PubMed Web of Science ®Google Scholar
• Ambudkar SV, Dey S, Hrycyna CA, et al. (1999). Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361–398
   PubMed Web of Science ®Google Scholar
• Ambudkar SV, Kim IW, Xia D, Sauna ZE. (2006). The A-loop, a novel conserved aromatic acid subdomain upstream of the Walker A motif in ABC transporters, is critical for ATP binding. FEBS Lett 580:1049–1055
   PubMed Web of Science ®Google Scholar
• Anderle P, Sengstag T, Mutch DM, et al. (2005). Changes in the transcriptional profile of transporters in the intestine along the anterior-posterior and crypt-villus axes. BMC Genomics 6:69
   PubMedGoogle Scholar
• Annilo T, Dean M. (2004). Degeneration of an ATP-binding cassette transporter gene, ABCC13, in different mammalian lineages. Genomics 84:34–46
   PubMed Web of Science ®Google Scholar
• Arienti C, Tesei A, Verdecchia GM, et al. (2013). Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer. Clin Colorectal Cancer 12:122–127
   PubMed Web of Science ®Google Scholar
• Auner V, Sehouli J, Oskay-Oezcelik G, et al. (2010). ABC transporter gene expression in benign and malignant ovarian tissue. Gynecol Oncol 117:198–201
   PubMed Web of Science ®Google Scholar
• Bader P, Schilling F, Schlaud M, et al. (1999). Expression analysis of multidrug resistance associated genes in neuroblastomas. Oncol Rep 6:1143–1146
   PubMed Web of Science ®Google Scholar
• Bakos E, Hegedus T, Hollo Z, et al. (1996). Membrane topology and glycosylation of the human multidrug resistance-associated protein. J Biol Chem 271:12322–12326
   PubMed Web of Science ®Google Scholar
• Bakos É, Homolya L. (2007). Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1). Pflugers Arch 453:621–641
   PubMed Web of Science ®Google Scholar
• Bakos E, Evers R, Sinkó E,et al. (2000). Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 57:760–768
   PubMed Web of Science ®Google Scholar
• Balatzenko G, Stoimenov A, Guenova M, et al. (2002). Application of reverse transcription polymerase chain reaction for analysis of multidrug resistance in patients with acute myeloblastic leukemia. J BUON 7:355–359
   PubMedGoogle Scholar
• Barnouin K, Leier I, Jedlitschky G, et al. (1998). Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione. Br J Cancer 77:201–209
   PubMed Web of Science ®Google Scholar
• Bart J, Hollema H, Groen HJ, et al. (2004). The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. Eur J Cancer 40:2064–2070
   PubMed Web of Science ®Google Scholar
• Berger W, Elbling L, Hauptmann E, Micksche M. (1997). Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells. Int J Cancer 73:84–93
   PubMed Web of Science ®Google Scholar
• Berger W, Setinek U, Hollaus P, et al. (2005). Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: Prognostic implications. J Cancer Res Clin Oncol 131:355–363
   PubMed Web of Science ®Google Scholar
• Biedler JL, Riehm H. (1970). Cellular resistance to actinomycin D in Chinese hamster cells in vitro: Cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 30:1174–1184
   PubMed Web of Science ®Google Scholar
• Bordow SB, Haber M, Madafiglio J, et al. (1994). Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplificationand overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res 54:5036–5040
   PubMed Web of Science ®Google Scholar
• Borel F, Han R, Visser A, et al. (2012). Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology 55:821–832
   PubMed Web of Science ®Google Scholar
• Borst P, Evers R, Kool M, Wijnholds J. (1999). The multidrug resistance protein family. Biochim Biophys Acta 1461:347–357
   PubMed Web of Science ®Google Scholar
• Boumendjel A, Baubichon-Cortay H, Trompier D, et al. (2005). Anticancer multidrug resistence mediated by MRP1: Recent advances in the discovery of reversal agents. Med Res Rev 25:453–472
   PubMed Web of Science ®Google Scholar
• Brandmann M, Tulpule K, Schmidt MM, Dringen R. (2012). The antiretroviral protease inhibitors indinavir and nelfinavir stimulate Mrp1-mediated GSH export from cultured brain astrocytes. J Neurochem 120:78–92
   PubMed Web of Science ®Google Scholar
• Brodeur GM. (2003). Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 3:203–216
   PubMed Web of Science ®Google Scholar
• Broyl A, Corthals SL, Jongen JL, et al. (2010). Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: A prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 11:1057–1065
   PubMed Web of Science ®Google Scholar
• Bryan J, Muñoz A, Zhang X, et al. (2007). ABCC8 and ABCC9: ABC transporters that regulate K+ channels. Pflugers Arch 453:703–718
   PubMed Web of Science ®Google Scholar
• Burkhart CA, Cheng AJ, Madafiglio J, et al. (2003). Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. J Natl Cancer Inst 95:1394–1403
   PubMed Web of Science ®Google Scholar
• Cecchin E, D’Andrea M, Lonardi S, et al. (2013). A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J 13:403–409
   Google Scholar
• Chan HS, Lu Y, Grogan TM, et al. (1997). Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. Cancer Res 57:2325–2330
   PubMed Web of Science ®Google Scholar
• Chauhan PS, Bhushan B, Singh LC, et al. (2012). Expression of genes related to multiple drug resistance and apoptosis in acute leukemia: Response to induction chemotherapy. Exp Mol Pathol 92:44–49
   PubMed Web of Science ®Google Scholar
• Chen ZS, Furukawa T, Sumizawa T, et al. (1999). ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol 55:921–928
   PubMed Web of Science ®Google Scholar
• Choudhuri S, Klassen CD. (2006). Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 25:231–259
   PubMed Web of Science ®Google Scholar
• Cole SP. (2014). Targeting multidrug resistance protein 1 (MRP1, ABCC1): Past, present, and future. Annu Rev Pharmacol Toxicol 54:95–117
   PubMed Web of Science ®Google Scholar
• Cole SP, Bhardwaj G, Gerlach JH, et al. (1992). Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650–1654
   PubMed Web of Science ®Google Scholar
• Cole SP, Sparks KE, Fraser K, et al. (1994). Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902–5910
   PubMed Web of Science ®Google Scholar
• Colombo S, Soranzo N, Rotger M, et al. (2005). Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet Genomics 15:599–608
   PubMed Web of Science ®Google Scholar
• Conrad S, Kauffmann HM, Ito K, et al. (2001). Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J Hum Genet 46:656–663
   PubMed Web of Science ®Google Scholar
• Conrad S, Kauffmann HM, Ito K, et al. (2002). A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics 12:321–330
   PubMedGoogle Scholar
• Conseil G, Cole SP. (2013). Two polymorphic variants of ABCC1 selectively alter drug resistance and inhibitor sensitivity of the multidrug and organic anion transporter multidrug resistance protein 1. Drug Metab Dispos 41:2187–2196
   PubMed Web of Science ®Google Scholar
• Conseil G, Deeley RG, Cole SP. (2005). Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet Genomics 15:523–533
   PubMed Web of Science ®Google Scholar
• Cutler MJ, Urquhart BL, Velenosi TJ, et al. (2012). In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna. J Clin Pharmacol 52:530–542
   PubMed Web of Science ®Google Scholar
• Dallas S, Zhu X, Baruchel S, et al. (2003). Functional expression of the multidrug resistance protein 1 in microglia. J Pharmacol Exp Ther 307:282–290
   PubMed Web of Science ®Google Scholar
• Dean M, Rzhetsky A, Allikmets R. (2001). The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11:1156–1166
   PubMed Web of Science ®Google Scholar
• Deeley RG, Westlake C, Cole SP. (2006). Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86:849–899
   PubMed Web of Science ®Google Scholar
• Diestra JE, Condom E, Del Muro XG, et al. (2003). Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: Biological and clinical implications. J Urol 170:1383–1387
   PubMed Web of Science ®Google Scholar
• Duffy CP, Elliott CJ, O’Connor RA, et al. (1998). Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer 34:1250–1259
   PubMed Web of Science ®Google Scholar
• Ehrlichova M, Mohelnikova-Duchonova B, Hrdy J, et al. (2013). The association of taxane resistance genes with the clinical course of ovarian carcinoma. Genomics 102:96–101
   PubMed Web of Science ®Google Scholar
• El Azreq MA, Naci D, Aoudjit F. (2012). Collagen/β1 integrin signaling up-regulates the ABCC1/MRP-1 transporter in an ERK/MAPK-dependent manner. Mol Biol Cell 23:3473–3484
   PubMed Web of Science ®Google Scholar
• El-Readi MZ, Eid S, Ashour ML, et al. (2013). Modulation of multidrug resistancein cancer cells by chelidonine and Chelidonium majus alkaloids. Phytomedicine 20:282–294
   PubMed Web of Science ®Google Scholar
• Elsby R, Smith V, Fox L, et al. (2011). Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions. Xenobiotica 41:764–783
   PubMed Web of Science ®Google Scholar
• Endo K, Maehara Y, Ichiyoshi Y, et al. (1996). Multidrug resistance-associated protein expression in clinical gastric carcinoma. Cancer 77:1681–1687
   PubMed Web of Science ®Google Scholar
• Evers R, Zaman GJ, van Deemter L, et al. (1996). Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest 97:1211–1218
   PubMed Web of Science ®Google Scholar
• Faggad A, Darb-Esfahani S, Wirtz R, et al. (2009). Expression of multidrug resistance-associated protein 1 in invasive ovarian carcinoma: Implication for prognosis. Histopathology 54:657–666
   PubMed Web of Science ®Google Scholar
• Ferguson LR, De Flora S. (2005). Multiple drug resistance, antimutagenesis and anticarcinogenesis. Mutat Res 591:24–33
   PubMed Web of Science ®Google Scholar
• Ferlay J, Parkin DM, Steliarova-Foucher E. (2010). Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765–781
   PubMed Web of Science ®Google Scholar
• Filipits M, Haddad V, Schmid K, et al. (2007). Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res 13:3892–3898
   PubMed Web of Science ®Google Scholar
• Filipits M, Malayeri R, Suchomel RW, et al. (1999). Expression of the multidrug resistance protein (MRP1) in breast cancer. Anticancer Res 19:5043–5049
   PubMed Web of Science ®Google Scholar
• Filipits M, Pohl G, Rudas M, et al. (2005). Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: The Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 23:1161–1168
   PubMed Web of Science ®Google Scholar
• Filipits M, Suchomel RW, Dekan G, et al. (1996). MRP and MDR1 gene expression in primary breast carcinomas. Clin Cancer Res 2:1231–1237
   PubMed Web of Science ®Google Scholar
• Flens MJ, Zaman GJ, van der Valk P, et al. (1996). Tissue distribution of the multidrug resistance protein. Am J Pathol 148:1237–1247
   PubMed Web of Science ®Google Scholar
• Foster NR, Mandrekar SJ, Schild SE, et al. (2009). Prognostic factors differ by tumor stage for small cell lung cancer: A pooled analysis of North Central Cancer Treatment Group trials. Cancer 115:2721–2731
   PubMed Web of Science ®Google Scholar
• Fukushima Y, Oshika Y, Tokunaga T, et al. (1999). Multidrug resistance-associated protein (MRP) expression is correlated with expression of aberrant p53 protein in colorectal cancer. Eur J Cancer 35:935–938
   PubMed Web of Science ®Google Scholar
• Gandhi L, Harding MW, Neubauer M, et al. (2007). A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer 109:924–932
   PubMed Web of Science ®Google Scholar
• Gao M, Cui HR, Loe DW, et al. (2000). Comparison of the functional characteristics of the nucleotide binding domains of multidrug resistance protein 1. J Biol Chem 275:13098–13108
   PubMed Web of Science ®Google Scholar
• Ge J, Chen Z, Wu S, et al. (2009). Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer. Digestion 80:148–158
   PubMed Web of Science ®Google Scholar
• Gennuso F, Fernetti C, Tirolo C, et al. (2004). Bilirubin protects astrocytes from its own toxicity by inducing up-regulation and translocation of multidrug resistance-associated protein 1 (Mrp1). Proc Natl Acad Sci USA 101:2470–2475
   PubMed Web of Science ®Google Scholar
• Germann UA, Shlyakhter D, Mason VS, et al. (1997). Cellular and biochemical characterization of VX-710 as a chemosensitizer: Reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 8:125–140
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Colleoni M, Domenighetti G, Gelber RD. (2003). Systemic treatments for women with breast cancer: Outcome with relation to screening for the disease. Ann Oncol 14:1212–1214
   PubMed Web of Science ®Google Scholar
• Goldman B. (2003). Multidrug resistance: Can new drugs help chemotherapy score against cancer? J Natl Cancer Inst 95:255–257
   PubMed Web of Science ®Google Scholar
• Gomez A, Ingelman-Sundberg M. (2009). Pharmacoepigenetics: Its role in interindividual differences in drug response. Clin Pharmacol Ther 85:426–430
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. (2002). Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2:48–58
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Pastan I, Ambudkar SV. (1996). P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 6:610–617
   PubMed Web of Science ®Google Scholar
• Grant CE, Kurz EU, Cole SP, Deeley RG. (1997). Analysis of the intron-exon organization of the human multidrug-resistance protein gene (MRP) and alternative splicing of its mRNA. Genomics 45:368–378
   PubMed Web of Science ®Google Scholar
• Greaves W, Xiao L, Sanchez-Espiridion B, et al. (2012). Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols. J Hematol Oncol 5:47. doi:10.1186/1756-8722-5-47
   PubMed Web of Science ®Google Scholar
• Gromicho M, Dinis J, Magalhães M, et al. (2011). Development of imatinib and dasatinib resistance: Dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1. Leuk Lymphoma 52:1980–1990
   PubMed Web of Science ®Google Scholar
• Grzywacz MJ, Yang JM, Hait WN. (2003). Effect of the multidrug resistance protein on the transport of the antiandrogen flutamide. Cancer Res 63:2492–2498
   PubMed Web of Science ®Google Scholar
• Gu L, Findley HW, Zhou M. (2002). MDM2 induces NF-kappaB/p65 expression transcriptionally through Sp1-binding sites: A novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia. Blood 99:3367–3375
   PubMed Web of Science ®Google Scholar
• Gutmann H, Török M, Fricker G, et al. (1999). Modulation of multidrug resistance protein expression in porcine brain capillary endothelial cells in vitro. Drug Metab Dispos 27:937–941
   PubMed Web of Science ®Google Scholar
• Haber M, Bordow S, Gilbert J, et al. (1999). Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells. Oncogene 18:2777–2782
   PubMed Web of Science ®Google Scholar
• Haber M, Smith J, Bordow SB, et al. (2006). Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol 24:1546–1553
   PubMed Web of Science ®Google Scholar
• Hait WN, Yang JM. (2006). The individualization of cancer therapy: The unexpected role of p53. Trans Am Clin Climatol Assoc 117:85–101
   Google Scholar
• Hayashi A, Suzuki H, Itoh K, et al. (2003). Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts. Biochem Biophys Res Commun 310:824–829
   PubMed Web of Science ®Google Scholar
• Henderson MJ, Haber M, Porro A, et al. (2011). ABCC multidrug transporters in childhood neuroblastoma: Clinical and biological effects independent of cytotoxic drug efflux. J Natl Cancer Inst 103:1236–1251
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Coleman RL, Markman M. (2009). Ovarian cancer. Lancet 374:1371–1382
   PubMed Web of Science ®Google Scholar
• Hermann DM, Kilic E, Spudich A, et al. (2006). Role of drug efflux carriers in the healthy and diseased brain. Ann Neurol 60:489–498
   PubMed Web of Science ®Google Scholar
• Hidaka H, Seki N, Yoshino H, et al. (2012). Tumor suppressive microRNA-1285 regulates novel molecular targets: Aberrant expression and functional significance in renal cell carcinoma. Oncotarget 3:44–57
   PubMedGoogle Scholar
• Higgins CF. (1992). ABC transporters: From microoganisms to man. Annu Rev Cell Biol 8:67–113
   PubMedGoogle Scholar
• Hinoshita E, Uchiumi T, Taguchi K, et al. (2000). Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin Cancer Res 6:2401–2407
   PubMed Web of Science ®Google Scholar
• Hipfner DR, Deeley RG, Cole SP. (1999). Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1461:359–376
   PubMed Web of Science ®Google Scholar
• Hipfner DR, Gauldie SD, Deeley RG, Cole SP. (1994). Detection of the M(r) 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res 54:5788–5792
   PubMed Web of Science ®Google Scholar
• Hlaváč V, Brynychová V, Václavíková R, et al. (2013). The expression profile of ABC transporter genes in breast carcinoma. Pharmacogenomics 14:515–529
   PubMed Web of Science ®Google Scholar
• Hlavata I, Mohelnikova-Duchonova B, Vaclavikova R, et al. (2012). The role of ABC transporters in progression and clinical outcome of colorectal cancer. Mutagenesis 27:187–196
   PubMed Web of Science ®Google Scholar
• Hodorová I, Rybárová S, Solár P, et al. (2008). Multidrug resistance proteins in renal cell carcinoma. Folia Biol (Praha) 54:187–192
   PubMed Web of Science ®Google Scholar
• Hoffmann K, Shibo L, Xiao Z, et al. (2011). Correlation of gene expression of ATP-binding cassette protein and tyrosine kinase signaling pathway in patients with hepatocellular carcinoma. Anticancer Res 31:3883–3890
   PubMed Web of Science ®Google Scholar
• Hoogeveen AT, Keulemans J, Willemsen R, et al. (1991). Immunological localization of cystic fibrosis candidate gene products. Exp Cell Res 193:435–437
   PubMed Web of Science ®Google Scholar
• Horiguchi S, Shiraha H, Nagahara T, et al. (2013). Loss of runt-related transcription factor 3 induces gemcitabine resistance in pancreatic cancer. Mol Oncol 7:840–849
   PubMed Web of Science ®Google Scholar
• Hsia TC, Lin CC, Wang JJ, et al. (2002). Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression. Lung 180:173–179
   PubMed Web of Science ®Google Scholar
• Husain AN. (2013). Lung. In: Kumar V, Abbas AK, Aster JC, eds. Robbins Basic Pathology. 9th ed. Philadelphia (PA): Elsevier/Saunders, 459–517
   Google Scholar
• Hyde SC, Emsley P, Hartshorn MJ, et al. (1990). Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 346:362–365
   PubMed Web of Science ®Google Scholar
• Innocenti F, Kroetz DL, Schuetz E, et al. (2009). Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 27:2604–2614
   PubMed Web of Science ®Google Scholar
• Iram SH, Cole SP. (2011). Expression and function of human MRP1 (ABCC1) is dependent on amino acids in cytoplasmic loop 5 and its interface with nucleotide binding domain 2. J Biol Chem 286:7202–7213
   PubMed Web of Science ®Google Scholar
• Ito S, Ieiri I, Tanabe M, et al. (2001). Polymorphisms of the ABC transporter genes, NDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 11:175–184
   PubMedGoogle Scholar
• Jedlitschky G, Tirschmann K, Lubenow LE, et al. (2004). The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. Blood 104:3603–3610
   PubMed Web of Science ®Google Scholar
• Jeha S. (2003). Who should be treating adolescents and young adults with acute lymphoblastic leukaemia? Eur J Cancer 39:2579–2583
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, Ward E. (2010). Cancer statistics, 2010. CA Cancer J Clin 60:277–300
   PubMed Web of Science ®Google Scholar
• Jungsuwadee P, Zhao T, Stolarczyk EI, et al. (2012). The G671V variant of MRP1/ABCC1 links doxorubicin-induced acute cardiac toxicity to disposition of the glutathione conjugate of 4-hydroxy-2-trans-nonenal. Pharmacogenet Genomics 22:273–284
   PubMed Web of Science ®Google Scholar
• Juszczynski P, Niewiarowski W, Krykowski E, et al. (2002). Expression of the multidrug resistanceassociated protein (mrp) gene in chronic lymphocytic leukemia. Leuk Lymphoma 43:153–158
   PubMed Web of Science ®Google Scholar
• Kamazawa S, Kigawa J, Kanamori Y, et al. (2002). Multidrug resistance gene-1 is a useful predictor of paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol 86:171–176
   PubMed Web of Science ®Google Scholar
• Kao A, Shiun SC, Hsu NY, et al. (2001). Technetium-99m methoxyisobutylisonitrile chest imaging for small-cell lung cancer. Relationship to chemotherapy response (six courses of combination of cisplatin and etoposide) and p-glycoprotein or multidrug resistance related protein expression. Ann Oncol 12:1561–1566
   PubMedGoogle Scholar
• Kartenbeck J, Leuschner U, Mayer R, Keppler D. (1996). Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology 23:1061–1066
   PubMed Web of Science ®Google Scholar
• Kato S, Ito K, Kato Y, et al. (2009). Involvement of multidrug resistance-associated protein 1 in intestinal toxicity of methotrexate. Pharm Res 26:1467–1476
   PubMed Web of Science ®Google Scholar
• Kigawa J, Minagawa Y, Cheng X, Terakawa N. (1998). Gamma-glutamyl cystein synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer. Clin Cancer Res 4:1737–1741
   PubMed Web of Science ®Google Scholar
• Kilic E, Spudich A, Kilic U, et al. (2008). ABCC1: A gateway for pharmacological compounds to the ischaemic brain. Brain 131:2679–2689
   PubMed Web of Science ®Google Scholar
• Kim H, Kim K, No JH, et al. (2012). Prognostic value of biomarkers related to drug resistance in patients with advanced epithelial ovarian cancer. Anticancer Res 32:589–594
   PubMed Web of Science ®Google Scholar
• Kim WJ, Kakehi Y, Kinoshita H, et al. (1996). Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP), glutathione-Stransferase- pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney. J Urol 156:506–511
   PubMed Web of Science ®Google Scholar
• Kim YH, Ishii G, Goto K, et al. (2009). Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer 65:105–111
   PubMed Web of Science ®Google Scholar
• König J, Hartel M, Nies AT, et al. (2005). Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int J Cancer 115:359–367
   PubMed Web of Science ®Google Scholar
• Ku JL, Shin YK, Kim DW, et al. (2010). Establishment and characterization of 13 human colorectal carcinoma cell lines: Mutations of genes and expressions of drug-sensitivity genes and cancer stem cell markers. Carcinogenesis 31:1003–1009
   PubMed Web of Science ®Google Scholar
• Kurz EU, Cole SP, Deeley RG. (2001). Identification of DNA-protein interactions in the 5′ flanking and 5′ untranslated regions of the human multidrug resistance protein (MRP1) gene: Evaluation of a putative antioxidant response element/AP-1 binding site. Biochem Biophys Res Commun 285:981–990
   PubMed Web of Science ®Google Scholar
• Lacueva J, Perez-Ramos M, Soto JL, et al. (2005). Multidrug resistance-associated protein (MRP1) gene is strongly expressed in gastric carcinomas. Analysis by immunohistochemistry and real-time quantitative RT-PCR. Histopathology 46:389–395
   PubMed Web of Science ®Google Scholar
• Langer R, Ott K, Feith M, et al. (2010). High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients. J Surg Oncol 102:503–508
   PubMed Web of Science ®Google Scholar
• Langer R, Specht K, Becker K, et al. (2005). Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin Cancer Res 11:7462–7469
   PubMed Web of Science ®Google Scholar
• Larkin A, O’Driscoll L, Kennedy S, et al. (2004). Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: A prognostic study. Int J Cancer 112:286–294
   PubMed Web of Science ®Google Scholar
• Lee JH, Um JW, Lee JH. (2012). Can immunohistochemistry of multidrug-resistant proteins replace the histoculture drug response assay in colorectal adenocarcinomas? Hepatogastroenterology 59:1075–1078
   PubMed Web of Science ®Google Scholar
• Leier I, Jedlitschky G, Buchholz U, et al. (1994). The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 269:27807–27810
   PubMed Web of Science ®Google Scholar
• Leonessa F, Clarke R. (2003). ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 10:43–73
   PubMed Web of Science ®Google Scholar
• Leschziner G, Zabaneh D, Pirmohamed M, et al. (2006). Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. Pharmacogenet Genomics 16:439–450
   PubMed Web of Science ®Google Scholar
• Leslie EM, Deeley RG, Cole SP. (2005). Multidrug resistance proteins: Role of P-glykoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216–237
   PubMed Web of Science ®Google Scholar
• Leslie EM, Deeley RG, Cole SP. (2001a). Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 167:3–23
   PubMed Web of Science ®Google Scholar
• Leslie EM, Mao Q, Oleschuk CJ, et al. (2001b). Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and ATPase activities by interaction with dietary flavonoids. Mol Pharmacol 59:1171–1180
   PubMed Web of Science ®Google Scholar
• Leslie EM, Létourneau IJ, Deeley RG, Cole SP. (2003). Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochemistry 42:5214–5224
   PubMed Web of Science ®Google Scholar
• Letourneau IJ, Deeley RG, Cole SP. (2005). Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1). Pharmacogenet Genomics 15:647–657
   PubMed Web of Science ®Google Scholar
• Li H, Zhou S, Li T, et al. (2012). Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference. Hepatogastroenterology 59:2238–2242
   PubMed Web of Science ®Google Scholar
• Li J, Li ZN, Yu LC, et al. (2010). Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy. Lung Cancer 69:116–122
   PubMed Web of Science ®Google Scholar
• Li J, Li ZN, Du YJ, et al. (2009). Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: Correlation with response to chemotherapy and survival. Clin Lung Cancer 10:414–421
   PubMed Web of Science ®Google Scholar
• Liang Z, Wu H, Xia J, et al. (2010). Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 79:817–824
   PubMed Web of Science ®Google Scholar
• Ling V. (1997). Multidrug resistance: Molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 40:S3–S8
   PubMed Web of Science ®Google Scholar
• Liscovitch M, Lavie Y. (2002). Cancer multidrug resistance: A review of recent drug discovery research. IDrugs 5:349–355
   PubMedGoogle Scholar
• Loe DW, Almquist KC, Deeley RG, Cole SP. (1996). Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem 271:9675–9682
   PubMed Web of Science ®Google Scholar
• Loe DW, Stewart RK, Massey TE, et al. (1997). ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. Mol Pharmacol 51:1034–1041
   PubMed Web of Science ®Google Scholar
• Loe DW, Deeley RG, Cole SP. (2000). Verapamil stimulates glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). J Pharmacol Exp Ther 293:530–538
   PubMed Web of Science ®Google Scholar
• Löscher W, Potschka H. (2005). Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2:86–98
   PubMedGoogle Scholar
• Lv H, He Z, Liu X, et al. (2007). Reversal of BCRP-mediated multidrug resistance by stable expression of small interfering RNAs. J Cell Biochem 102:75–81
   PubMed Web of Science ®Google Scholar
• Maliepaard M, Scheffer GL, Faneyte IF, et al. (2001). Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458–3464
   PubMed Web of Science ®Google Scholar
• Manohar CF, Bray JA, Salwen HR, et al. (2004). MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma. Oncogene 23:753–762
   PubMed Web of Science ®Google Scholar
• Marsh S, Paul J, King CR, et al. (2007). Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 25:4528–4535
   PubMed Web of Science ®Google Scholar
• Mbuna J, Kaneta T, Imasaka T. (2011). Rapid determination of multidrug resistance-associated protein in cancer cells by capillary electrophoresis immunoassay. J Chromatogr A 1218:3923–3927
   PubMed Web of Science ®Google Scholar
• Merk J, Rolff J, Dorn C, et al. (2011). Chemoresistance in non-small-cell lung cancer: Can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy? Eur J Cardiothorac Surg 40:e29–e33
   PubMed Web of Science ®Google Scholar
• Michaelis M, Rothweiler F, Klassert D, et al. (2009). Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res 69:416–421
   PubMed Web of Science ®Google Scholar
• Minderman H, O’Loughlin KL, Pendyala L, Baer MR. (2004). VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res 10:1826–1834
   PubMed Web of Science ®Google Scholar
• Mody R, Li S, Dover DC, et al. (2008). Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study. Blood 111:5515–5523
   PubMed Web of Science ®Google Scholar
• Mohelnikova-Duchonova B, Brynychova V, Oliverius M, et al. (2013). Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and non-neoplastic tissues. Pancreas 42:707–716
   PubMed Web of Science ®Google Scholar
• Moitra K, Lou H, Dean M. (2011). Multidrug efflux pumps and cancer stem cells: Insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther 89:491–502
   PubMed Web of Science ®Google Scholar
• Morrow CS, Peklak-Scott C, Bishwokarma B, et al. (2006). Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol Pharmacol 69:1499–1505
   PubMed Web of Science ®Google Scholar
• Mueller S, Matthay KK. (2009). Neuroblastoma: Biology and staging. Curr Oncol Rep 11:431–438
   PubMed Web of Science ®Google Scholar
• Muller M, Yong M, Peng XH, et al. (2001). Evidence for the role of glycosylation in accessibility of the extracellular domains of human MRP1 (ABCC1). Biochemistry 41:10123–10132
   Web of Science ®Google Scholar
• Mulrooney DA, Yeazel MW, Kawashima T, et al. (2009). Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b4606
   PubMed Web of Science ®Google Scholar
• Myette RL, Conseil G, Ebert SP, et al. (2013). Chalcogenopyrylium dyes as differential modulators of organic anion transport by multidrug resistance protein 1 (MRP1), MRP2, and MRP4. Drug Metab Dispos 41:1231–1239
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. (2010). NCCN clinical practice guidelines in oncology™. Breast Cancer V.2.2010. Available from: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf [last accessed 24 May 2010]
   Google Scholar
• Nooter K, de la Riviere GB, Klijn J, et al. (1997a). Multidrug resistance protein in recurrent breast cancer. Lancet 349:1885–1886
   PubMed Web of Science ®Google Scholar
• Nooter K, de la Riviere GB, Look MP, et al. (1997b). The prognostic significance of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer 76:486–493
   PubMed Web of Science ®Google Scholar
• Norris MD, Bordow SB, Marshall GM, et al. (1996). Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 334:231–238
   PubMed Web of Science ®Google Scholar
• O’Connor R. (2007). The pharmacology of cancer resistance. Anticancer Res 27:1267–1272
   PubMed Web of Science ®Google Scholar
• O’Connor R, Heenan M, Connolly L, et al. (2004). Increased anti.tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. Anticancer Res 24:457–464
   PubMed Web of Science ®Google Scholar
• O’Connor R, O’Leary M, Ballot J, et al. (2007). A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother Pharamacol 59:79–87
   PubMed Web of Science ®Google Scholar
• Obata H, Yahata T, Quan J, et al. (2006). Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer. Anticancer Res 26:2227–2232
   PubMed Web of Science ®Google Scholar
• O’Driscoll L, Walsh N, Larkin A, et al. (2007). MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma. Anticancer Res 27:2115–2120
   PubMed Web of Science ®Google Scholar
• Ohishi Y, Oda Y, Uchiumi T, et al. (2002). ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin Cancer Res 8:3767–3775
   PubMed Web of Science ®Google Scholar
• Ohtsuki S, Kamoi M, Watanabe Y, et al. (2007). Correlation of induction of ATP binding cassette transporter A5 (ABCA5) and ABCB1 mRNAs with differentiation state of human colon tumor. Biol Pharm Bull 30:1144–1146
   PubMed Web of Science ®Google Scholar
• Oselin K, Mrozikiewicz PM, Gaikovitch E, et al. (2003). Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: Detection of a novel mutation G816A in the human MRP1 gene. Eur J Clin Pharmacol 59:347–350
   PubMed Web of Science ®Google Scholar
• Ostrow JD, Pascolo L, Brites D, Tiribelli C. (2004). Molecular basis of bilirubin-induced neurotoxicity. Trends Mol Med 10:65–70
   PubMed Web of Science ®Google Scholar
• Oudard S, Banu E, Beuzeboc P, et al. (2005). Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23:3343–3351
   PubMed Web of Science ®Google Scholar
• Oudard S, Levalois C, Andrieu JM, et al. (2002). Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome. Anticancer Res 22:121–128
   PubMed Web of Science ®Google Scholar
• Ozvegy-Laczka C, Cserepes J, Elkind NB, Sarkadi B. (2005). Tyrosine kinase inhibitor resistance in cancer: Role of ABC multidrug transporters. Drug Resist Update 8:15–26
   PubMed Web of Science ®Google Scholar
• Pajic M, Murray J, Marshall GM, et al. (2011). ABCC1 G2012T single nucleotide polymorphism is associated with patient outcome in primary neuroblastoma and altered stability of the ABCC1 gene transcript. Pharmacogenet Genomics 21:270–279
   PubMed Web of Science ®Google Scholar
• Pan YZ, Zhou A, Hu Z, Yu AM. (2013). Small nucleolar RNA-derived microRNA hsa-Mir-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Drug Metab Dispos 41:1744–1751
   PubMed Web of Science ®Google Scholar
• Patak P, Jin F, Schäfer ST, et al. (2011). The ATP-binding cassette transporters ABCB1 and ABCC1 are not regulated by hypoxia in immortalised human brain microvascular endothelial cells. Exp Transl Stroke Med 3:12
   PubMedGoogle Scholar
• Peng KC, Cluzeaud F, Bens M, et al. (1999). Tissue and cell distribution of the multidrug resistance-associated protein (MRP) in mouse intestine and kidney. J Histochem Cytochem 47:757–768
   PubMed Web of Science ®Google Scholar
• Perdu J, Germain, DP. (2001). Identification of novel polymorphisms in the pM5 and MRP1 (ABCC1) genes at locus 16p13.1 and exclusion of both genes as responsible for pseudoxanthoma elasticum. Hum Mutat 17:74–75
   PubMed Web of Science ®Google Scholar
• Petrylak DP. (2006). The treatment of hormone-refractory prostate cancer: Docetaxel and beyond. Rev Urol 8:S48–S55
   PubMedGoogle Scholar
• Plasschaert SL, de Bont ES, Boezen M, et al. (2005). Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res 11:8661–8668
   PubMed Web of Science ®Google Scholar
• Porro A, Haber M, Diolaiti D, et al. (2010). Direct and coordinate regulation of ATP-binding cassette transporter genes by Myc factors generates specific transcription signatures that significantly affect the chemoresistance phenotype of cancer cells. J Biol Chem 285:19532–19543
   PubMed Web of Science ®Google Scholar
• Pulte D, Gondos A, Brenner H. (2009). Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood 113:1408–1411
   PubMed Web of Science ®Google Scholar
• Qin L, Zheng J, Grant CE, et al. (2008). Residues responsible for the asymmetric function of the nucleotide binding domains of multidrug resistance protein 1. Biochemistry 47:13952–13965
   PubMed Web of Science ®Google Scholar
• Ramaen O, Leulliot N, Sizun C, et al. (2006). Structure of the human multidrug resistance protein 1 nucleotide binding domain 1 bound to Mg2+/ATP reveals a non-productive catalytic site. J Mol Biol 359:940–949
   PubMed Web of Science ®Google Scholar
• Ramjeesingh M, Li C, Garami E, et al. (1999). Walker mutations reveal loose relationship between catalytic and channel-gating activities of purified CFTR (cystic fibrosis transmembrane conductance regulator). Biochemistry 38:1463–1468
   PubMed Web of Science ®Google Scholar
• Reeves DJ, Liu CY. (2009). Treatment of metastatic renal cell carcinoma. Cancer Chemother Pharmacol 64:11–25
   Google Scholar
• Robey RW, Lin B, Qiu J, et al. (2011). Rapid detection of ABC transporter interaction: Potential utility in pharmacology. J Pharmacol Toxicol Methods 63:217–222
   PubMed Web of Science ®Google Scholar
• Roelofsen H, Vos TA, Schippers IJ, et al. (1997). Increased levels of the multidrug resistance protein in lateral membranes of proliferating hepatocyte-derived cells. Gastroenterology 112:511–521
   PubMed Web of Science ®Google Scholar
• Rudas M, Filipits M, Taucher S, et al. (2003). Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy. Breast Cancer Res Treat 81:149–157
   PubMed Web of Science ®Google Scholar
• Rungsardthong K, Mares-Sámano S, Penny J. (2012). Virtual screening of ABCC1 transporter nucleotidebinding domains as a therapeutic target in multidrug resistant cancer. Bioinformation 8:907–911
   PubMedGoogle Scholar
• Saito S, Iida A, Sekine A, et al. (2002). Identification of 779 genetic variations in eight genes encoding the members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR). J Hum Genet 47:147–171
   PubMed Web of Science ®Google Scholar
• Sakaeda T, Nakamura T, Okumura K. (2004). Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. Curr Top Med Chem 4:1385–1398
   PubMed Web of Science ®Google Scholar
• Sampath J, Sun D, Kidd VJ, et al. (2001). Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 276:39359–39367
   PubMed Web of Science ®Google Scholar
• Seeger RC, Brodeur GM, Sather H, et al. (1985). Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313:1111–1116
   PubMed Web of Science ®Google Scholar
• Seiden MV, Swenerton KD, Matulonis U, et al. (2002). A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol 86:302–310
   PubMed Web of Science ®Google Scholar
• Semsei AF, Erdelyi DJ, Ungvari I, et al. (2012). ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia. Cell Biol Int 36:79–86
   PubMed Web of Science ®Google Scholar
• Shankar SM, Marina N, Hudson MM, et al. (2008). Monitoring for cardiovascular disease in survivors of childhood cancer: Report from the Cardiovascular Disease Task Force of the Children’s Oncology Group. Pediatrics 121:e387–e396
   PubMed Web of Science ®Google Scholar
• Shiau YC, Tsai SC, Wang JJ, et al. (2001). To predict chemotherapy response using technetium-99m tetrofosmin and compare with p-glycoprotein and multidrug resistance related protein-1 expression in patients with untreated small cell lung cancer. Cancer Lett 169:181–188
   PubMed Web of Science ®Google Scholar
• Schaub TP, Kartenbeck J, König J, et al. (1999). Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol 10:1159–1169
   PubMed Web of Science ®Google Scholar
• Schwab M. (2004). MYCN in neuronal tumours. Cancer Lett 204:179–187
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. (2013). Cancer statistics, 2013. CA Cancer J Clin 63:11–30
   PubMed Web of Science ®Google Scholar
• Sissung TM, Baum CE, Kirkland CT, et al. (2010). Pharmacogenetics of membrane transporters: An update on current approaches. Mol Biotechnol 44:152–167
   PubMed Web of Science ®Google Scholar
• Smith PC, Karpowich N, Millen L, et al. (2002). ATP binding to the motor domain from an ABC transporter drives formation of a nucleotide sandwich dimer. Mol Cell 10:139–149
   PubMed Web of Science ®Google Scholar
• Slapak CA, Fracasso PM, Martell RL, et al. (1994). Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells. Cancer Res 54:5607–5613
   PubMed Web of Science ®Google Scholar
• Spudich A, Kilic E, Xing H, et al. (2006). Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischaemia. Nat Neurosci 9:487–488
   PubMed Web of Science ®Google Scholar
• Srimunta U, Sawanyawisuth K, Kraiklang R, et al. (2012). High expression of ABCC1 indicates poor prognosis in intrahepatic cholangiocarcinoma. Asian Pac J Cancer Prev 13:125–130
   PubMed Web of Science ®Google Scholar
• Stolarczyk EI, Reiling CJ, Pickin KA, et al. (2012). Casein kinase 2α regulates multidrug resistance-associated protein 1 function via phosphorylation of Thr249. Mol Pharmacol 82:488–499
   PubMed Web of Science ®Google Scholar
• St. Pierre MV, Serrano MA, Macias RI, et al. (2000). Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol 279:R1495–R1503
   PubMed Web of Science ®Google Scholar
• Sugiyama D, Kusuhara H, Lee YJ, Sugiyama Y. (2003). Involvement of multidrug resistance associated protein 1 (Mrp1) in the efflux transport of 17beta estradiol-D-17beta-glucuronide (E217betaG) across the blood-brain barrier. Pharm Res 20:1394–1400
   PubMed Web of Science ®Google Scholar
• Sullivan GF, Amenta PS, Villanueva JD, et al. (1998). The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 4:1393–1403
   PubMed Web of Science ®Google Scholar
• Sullivan GF, Yang JM, Vassil A, et al. (2000). Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. J Clin Invest 105:1261–1267
   PubMed Web of Science ®Google Scholar
• Sun Z, Chen J, Aakre J, et al. (2010). Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients. Ann Oncol 21:2011–2016
   PubMed Web of Science ®Google Scholar
• Suzuki H, Sugiyama Y. (1998). Excretion of GSSG and glutathione conjugates mediated by MRP1 and cMOAT/MRP2. Semin Liver Dis 18:359–376
   PubMed Web of Science ®Google Scholar
• Szakács G, Annereau JP, Lababidi S, et al. (2004). Predicting drug sensitivity and resistance: Profiling ABC transporter genes in cancer cells. Cancer Cell 6:129–137
   PubMed Web of Science ®Google Scholar
• Szakács G, Ozvegy C, Bakos E, et al. (2000). Transitionstate formation in ATPase-negative mutants of human MDR1 protein. Biochem Biophys Res Commun 276:1314–1319
   PubMed Web of Science ®Google Scholar
• Szakács G, Paterson JK, Ludwig JA, et al. (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219–234
   PubMed Web of Science ®Google Scholar
• Tada Y, Wada M, Migita T, et al. (2002). Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin. Int J Cancer 98:630–635
   PubMed Web of Science ®Google Scholar
• Tanaka M, Okazaki T, Suzuki H, et al. (2011). Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome. Cancer 117:744–751
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, et al. (1987). Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735–7738
   PubMed Web of Science ®Google Scholar
• Thomas F, Motsinger-Reif AA, Hoskins JM, et al. (2011). Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. Br J Cancer 105:1654–1662
   PubMed Web of Science ®Google Scholar
• Thomas H, Coley HM. (2003). Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10:159–165
   PubMedGoogle Scholar
• Toyoda Y, Hagiya Y, Adachi T, et al. (2008). MRP class of human ATP binding cassette (ABC) transporters: Historical background and new research directions. Xenobiotica 38:833–862
   PubMed Web of Science ®Google Scholar
• Tribull TE, Bruner RH, Bain LJ. (2003). The multidrug resistance associated protein 1 transports methoxychlor and protects the seminiferous epithelium from injury. Toxicol Lett 142:61–70
   PubMed Web of Science ®Google Scholar
• Triller N, Korosec P, Kern I, et al. (2006). Multidrug resistance in small cell lung cancer: Expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. Lung Cancer 54:235–240
   PubMed Web of Science ®Google Scholar
• Trnková Z, Bedrlíková R, Marková J, et al. (2007). Semiquantitative RT-PCR evaluation of the MDR1 gene expression in patients with acute myeloid leukemia. Neoplasma 54:383–390
   PubMed Web of Science ®Google Scholar
• Urquhart BL, Kim RB. (2009). Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol 65:1063–1070
   PubMed Web of Science ®Google Scholar
• Ushijima R, Takayama K, Izumi M, et al. (2007). Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer. Anticancer Res 27:4351–4358
   PubMed Web of Science ®Google Scholar
• van den Heuvel-Eibrink MM, Sonneveld P, Pieters R. (2000). The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther 38:94–110
   PubMed Web of Science ®Google Scholar
• van den Heuvel-Eibrink MM, van der Holt B, Burnett AK, et al. (2007). CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol 86:329–337
   PubMed Web of Science ®Google Scholar
• Vassilev LT. (2007). MDM2 inhibitors for cancer therapy. Trends Mol Med 13:23–31
   PubMed Web of Science ®Google Scholar
• Viale PH, Yamamoto DS. (2008). Cardiovascular toxicity associated with cancer treatment. Clin J Oncol Nurs 12:627–638
   PubMed Web of Science ®Google Scholar
• Vogiatzi P, Cassone M, Claudio L, Claudio PP. (2009). Targeted therapy for advanced prostate cancer: Looking through new lenses. Drug News Perspect 22:593–601
   PubMed Web of Science ®Google Scholar
• Vulsteke C, Lambrechts D, Dieudonné A, et al. (2013). Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Ann Oncol 24:1513–1525
   PubMed Web of Science ®Google Scholar
• Walsh N, Kennedy S, Larkin AM, et al. (2010). Membrane transport proteins in human melanoma: Associations with tumour aggressiveness and metastasis. Br J Cancer 102:1157–1162
   PubMed Web of Science ®Google Scholar
• Walsh N, Larkin A, Kennedy S, et al. (2009). Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol 9:6
   PubMedGoogle Scholar
• Walter RB, Raden BW, Hong TC, et al. (2003). Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 102:1466–1473
   PubMed Web of Science ®Google Scholar
• Wang L, Giannoudis A, Lane S, et al. (2008). Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 83:258–264
   PubMed Web of Science ®Google Scholar
• Wang Z, Sew PH, Ambrose H, et al. (2006). Nucleotide sequence analyses of the MRP1 gene in four populations suggest negative selection on its coding region. BMC Genomics 7:111
   PubMedGoogle Scholar
• Wang Z, Wang B, Tang K, et al. (2005). A functional polymorphism within the MRP1 gene locus identified through its genomic signature of positive selection. Hum Mol Genet 14:2075–2087
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith RL, Campalani E, et al. (2008). Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol 128:1925–1929
   PubMed Web of Science ®Google Scholar
• Williams GC, Liu A, Knipp G, Sinko PJ. (2002). Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother 46:3456–3462
   PubMed Web of Science ®Google Scholar
• Wojnowski L, Kulle B, Schirmer M, et al. (2005). NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112:3754–3762
   PubMed Web of Science ®Google Scholar
• Wright SR, Boag AH, Valdimarsson G, et al. (1998). Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung. Clin Cancer Res 4:2279–2289
   PubMed Web of Science ®Google Scholar
• Xia CQ, Smith PG. (2012). Drug efflux transporters and multidrug resistance in acute leukemia: Therapeutic impact and novel approaches to mediation. Mol Pharmacol 82:1008–1021
   PubMed Web of Science ®Google Scholar
• Yamada A, Ishikawa T, Ota I, et al. (2013). High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival. Breast Cancer Res Treat 137:773–782
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Matsuda Y, Tasaki T, et al. (2012). Induction of DNA strand breaks is critical to predict the cytotoxicity of gemtuzumab ozogamicin against leukemic cells. Cancer Sci 103:1722–1729
   PubMed Web of Science ®Google Scholar
• Yanagisawa T, Newman A, Coley H, et al. (1999). BIRICODAR (VX-710; Incel): An effective chemosensitizer in neuroblastoma. Br J Cancer 80:1190–1196
   PubMed Web of Science ®Google Scholar
• Yeh JJ, Hsu NY, Hsu WH, et al. (2005). Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer. Lung 183:177–183
   PubMed Web of Science ®Google Scholar
• Yin J, Zhang J. (2011). Multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphism: From discovery to clinical application. Zhong Nan Da Xue Xue Bao Yi Xue Ban 36:927–938
   PubMedGoogle Scholar
• Yin JY, Huang Q, Yang Y, et al. (2009). Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet Genomics 19:206–216
   PubMed Web of Science ®Google Scholar
• Yin JY, Han LF, Huang Q, et al. (2011). ABCC1 polymorphism Arg723Gln (2168G > A) is associated with lung cancer susceptibility in a Chinese population. Clin Exp Pharmacol Physiol 38:632–637
   PubMed Web of Science ®Google Scholar
• Yokoi T, Nakajima M. (2013). microRNAs as mediators of drug toxicity. Annu Rev Pharmacol Toxicol 53:377–400
   PubMed Web of Science ®Google Scholar
• Young LC, Campling BG, Voskoglou-Nomikos T, et al. (1999). Expression of multidrug resistance protein-related genes in lung cancer: Correlation with drug response. Clin Cancer Res 5:673–680
   PubMed Web of Science ®Google Scholar
• Yu AM. (2009). Role of microRNAs in the regulation of drug metabolism and disposition. Expert Opin Drug Metab Toxicol 5:1513–1528
   PubMed Web of Science ®Google Scholar
• Zajchowski DA, Karlan BY, Shawver LK. (2012). Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas. Mol Cancer Ther 11:492–502
   PubMed Web of Science ®Google Scholar
• Zalcberg J, Hu XF, Slater A, et al. (2000). MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines. Prostate Cancer Prostatic Dis 3:66–75
   PubMed Web of Science ®Google Scholar
• Zaman GJ, Flens MJ, van Leusden MR, et al. (1994). The human multidrug resistanceassociated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 91:8822–8826
   PubMed Web of Science ®Google Scholar
• Zaman GJ, Lankelma J, van Tellingen O, et al. (1995). Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci USA 92:7690–7694
   PubMed Web of Science ®Google Scholar
• Zhang W, Shannon WD, Duncan J, et al. (2006). Expression of drug pathway proteins is independent of tumour type. J Pathol 209:213–219
   PubMed Web of Science ®Google Scholar
• Zhang Y, Schuetz JD, Elmquist WF, Miller DW. (2004). Plasma membrane localization of multidrug resistance-associated protein homologues in brain capillary endothelial cells. J Pharmacol Exp Ther 311:449–455
   PubMed Web of Science ®Google Scholar
• Zhao J, Yu BY, Wang DY, Yang JE. (2010). Promoter polymorphism of MRP1 associated with reduced survival in hepatocellular carcinoma. World J Gastroenterol 16:6104–6110
   PubMed Web of Science ®Google Scholar
• Zimmermann C, Gutmann H, Hruz P, et al. (2005). Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metab Dispos 33:219–224
   PubMed Web of Science ®Google Scholar